Investigating infections after spleen removal in cancer patients
Overwhelming Post-Splenectomy Infections (OPSI) After Cytoreductive Surgery and Hyperthemic Intraperitoneal Chemotherapy: a Prospective Observational Study
This study looks at cancer patients who have had their spleen removed to see how often they get infections and how well they follow their antibiotic prescriptions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 79 Years |
| Sex | All |
| Sponsor | Hampshire Hospitals NHS Foundation Trust Academic / other |
| Locations | 1 site (Basingstoke, Hampshire) |
| Trial ID | NCT05718726 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients who have undergone splenectomy alongside complete cytoreductive surgery for peritoneal malignancies. It aims to assess the incidence of overwhelming post-splenectomy infections (OPSI) and evaluate patient compliance with prescribed prophylactic antibiotics. Participants will be contacted via telephone to gather data on their experiences and health outcomes following surgery. The study seeks to provide insights into the effectiveness and risks associated with current infection prevention strategies in this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 who have had a splenectomy in conjunction with complete cytoreductive surgery for any pathology.
Not a fit: Patients under 18 or over 80, those unable to provide informed consent, or those on immunosuppression therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve infection prevention strategies for patients undergoing splenectomy, enhancing their post-operative care.
How similar studies have performed: While the approach of assessing OPSI in splenectomy patients is established, the specific focus on compliance with prophylactic antibiotics in this context is less explored, indicating a novel aspect of this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients aged \>18 and \<80 years Patients capable of providing informed consent Patients who have a splenectomy in conjunction with complete cytoreductive surgery (CRS) for any pathology Exclusion Criteria: \- Patients who are \<18 and \>80 Patients who do not provide informed consent Patients on immunosuppression therapy
Where this trial is running
Basingstoke, Hampshire
- The Peritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust — Basingstoke, Hampshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Brendon Moran — Hampshire Hospitals NHS Foundation Trust
- Study coordinator: Victoria Corner
- Email: victoria.corner@hhft.nhs.uk
- Phone: 01962 824127
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.